India's pharmaceutical industry is characterized by expansion in research-and-development activities, rising product penetration into regulated markets, and by a widening array of products, says Indoco Remedies Chairman Suresh G. Kare. Kare says India's low-cost, high-standard pharmaceutical services are making India a center for contract research and manufacturing services (CRAMs) worldwide. He sees India's pharmaceutical market generating a total of $30 billion annually by 2010. Indoco specializes in manufacturing and marketing finished pharmaceutical products and active ingredients for regulated markets. Kare says global pharmaceutical companies are facing increasing research-and-development cost combined with falling productivity, and this is driving business to India and China. In terms of high standards, Kare notes that "India has the highest number of manufacturing plants approved by the U.S. FDA, in fact second only to the U.S." He adds that "the introduction of product patent in India has brought about some fundamental changes in strategies of the pharmaceutical companies, with focus shifting more towards R&D." (Click here for more
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
